Table 1.
Publications on the potential role of CHB in NAFLD onset.
| References | Year of publication | Number of patients | Explored association between CHB and NAFLD onset | OR, RR, or HR |
| Wong et al[38] | 2012 | 1030 | HBsAg seropositivity and fatty liver | 0.42 (0.20–0.88) |
| Cheng et al[44] | 2013 | 33,439 | HBsAg seropositivity and fatty liver | 0.70 (0.64–0.76) |
| Huang et al[40] | 2020 | 14,452 | HBsAg seropositivity and NAFLD | 0.72 (0.61–0.85) |
| Wang et al[41] | 2018 | 1882 | HBsAg seropositivity and NAFLD | 0.57 (0.34–0.98) |
| Lin et al[42] | 2021 | 4734 | HBsAg seropositivity and NAFLD | 0.83 (0.78–0.89) |
| Lv et al[43] | 2021 | 16,451 | HBsAg seropositivity and hypercholesterolemia | 0.62 (0.58–0.66) |
| Zhong et al[39] | 2018 | 2988 | HBsAg seropositivity and NAFLD | 0.64 (0.42–0.95) |
| Yun et al[47] | 2009 | 86 | HBsAg seropositivity and hypercholesterolemia | 1.19 (1.17–2.83) |
| Joo et al[37] | 2017 | 83,339 | HBsAg seropositivity and NAFLD | 0.83 (0.73–0.94) |
| Zhu et al[45] | 2019 | 4429 | HBV DNA levels and NAFLD | 0.37 (0.14–0.98) |
CHB: Chronic hepatitis B; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; HR: Hazard ratio; NAFLD: Non-alcoholic fatty liver disease; RR: Relative risk; OR: Odds ratio.